公开(公告)号：US20240058375A1

公开(公告)日：2024-02-22

申请号：US18260190

申请日：2021-10-27

Applicant: Purdue Research Foundation

Inventor： Qi ZHOU ,  Maizbha Uddin AHMED ,  Mohammad Abul Kalam AZAD ,  Jian LI

IPC: A61K31/785 ,  A61K38/12 ,  A61K9/00

CPC classification number: A61K31/785 ,  A61K38/12 ,  A61K9/0073 ,  A61K9/0075

Abstract: The present disclosure generally relates to a method for reducing the toxicity of polymyxins as a therapeutic agent comprising the step of coadministration of an aminoglycoside; a method for improving the aerosolization of an aminoglycoside comprising the step of combination formulation with a polymyxin; and a process for manufacturing a dry powder composition comprising a polymyxin and aminoglycoside. Pharmaceutical compositions and methods of treatment for lung infections are within the scope of this invention.

公开(公告)号：US20230099696A1

公开(公告)日：2023-03-30

申请号：US17908492

申请日：2021-03-05

Applicant: Purdue Research Foundation

Inventor： Qi ZHOU ,  Chune ZHU

IPC: A61K38/12 ,  A61K9/16 ,  A61K9/19

Abstract: The present disclosure generally relates to a process for manufacturing a microparticle composite or a dry powder inhaler composition of polymyxin and CFTR activator or CFTR potentiator comprising the steps preparing a suspension of nanoparticles (NPs) of CFTR activator or CFTR potentiator or their combinations; mixing the suspension of NPs with a solution of polymyxin and a solution of leucine, then followed by drying to afford said micro-particle composite or dry powder inhaler composition. Pharmaceutical compositions and methods for treating a patient of cystic fibrosis (CF) and/or a lung infection are within the scope of this invention.